The @fda.gov has approved tucatinib (Tukysa) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable, locally advanced or metastatic HER2-positive breast cancer following induction therapy. Link in the comments 👇

#LabLife 🔬 A little glimpse into our lab routine! Kirill Kriukov, Mira and Alisa Potapova at the microscope 🔬🧪

The FDA has granted accelerated approval to camizestrant (Etcamah) in combination with a CDK4/6 inhibitor - abemaciclib, palbociclib, or ribociclib for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer. Link in the comments 👇

The @fda.gov has approved zanidatamab-hrii (Ziihera) in combination with tislelizumab-jsgr and chemotherapy for adults with HER2-positive, unresectable locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma. Link in the comments 👇

In a new Cell review, Douglas Hanahan revisits one of the most influential frameworks in cancer biology. Link in the comments 👇 #HallmarksOfCancer #CancerResearch #Oncology #TumorMicroenvironment #CancerBiology #PrecisionMedicine

The FDA has approved iberdomide (Zenbexus) in combination with daratumumab and hyaluronidase-fihj plus dexamethasone (IberDd) for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. Link in the comments 👇

We were happy to meet the new students as part of the Hong Kong Hospitality Program at CityU! 💙 It was a pleasure getting to know everyone and welcoming the new members of our community. Looking forward to everything ahead! ✨ #CityU #HongKongHospitalityProgram #StudentLife #HongKong #Welcome

A major limitation of many antibody–drug conjugates (ADCs) and small molecule–drug conjugates (SMDCs) is their dependence on receptor-mediated endocytosis: the drug must enter the cell before releasing its payload. Link in the comments 👇

The @fda.gov has approved Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed after prior PD-1–based therapy. Link in the comments 👇

This week came with a very special reason to celebrate! 🎂✨ We got together to wish our wonderful PI, Dr. Masha, a very Happy Birthday! 💙 Thank you for everything you bring to the lab, from your guidance and support to all the science and good moments we share together.

A new study in Cell Chemical Biology explored how the mechanism driving oncogene overexpression can determine the effectiveness of protein degraders such as PROTACs. Link in the comments 👇 #TargetedProteinDegradation #PROTAC #CancerResearch #DrugDiscovery #Oncology

The @fda.gov has approved the first gene therapy for children with Sanfilippo syndrome type A. Link in the comments 👇 #ClinicalMondays #GeneTherapy #SanfilippoSyndrome #Pediatrics #OrphanDrug #FastTrack #BreakthroughTherapy

#LabLife Sharing some experience from 2 days with LARU buddies Alisa Potapova and Kirill Kriukov. Just processed around 75 mice, collecting tumors and organs. A lot of analysis is still ahead, but at least this part is done! #LARU #Research #TeamScience #CancerResearch

The @fda.gov has approved the first therapy for glycogen storage disease type Ia (GSDIa). Genglycos (pariglasgene brecaparvovec-opnr) received accelerated approval for patients aged 8 years and older. Link in the comments 👇 #ClinicalMondays #GeneTherapy #RareDisease #GSDIa #FDA

#LabLife Dasha is sharing flow cytometry life hacks with Alisa and Mira🧪✨ #LabLife #FlowCytometry #Research #TeamScience

Researchers developed ProteinTalks, an AI-based virtual cell model that predicts how cancer cells respond to drugs by tracking changes in their proteins over time. Link in the comments 👇 #ScientificWednesdays #Proteomics #AI #DrugDiscovery #CancerResearch

Merck and Moderna have announced positive top-line results from the Phase 3 INTerpath-001 trial of intismeran autogene (V940) + pembrolizumab in patients with resected high-risk melanoma. Link in the comments 👇 #ClinicalMondays #Melanoma #CancerVaccine #mRNA #Immunotherapy

#LabLife Welcome Mira and Lucy! 🧪✨ 🦠 Mira joins us as a new Research Assistant, with an interest in microbiome-cancer interactions. 🔬 Lucy joins us as our Lab Manager and is interested in forensic pathology. So happy to have you both on the team! 💙

A new @cellpress.bsky.social study analyzed 262 solid tumors across 18 tumor types using spatial transcriptomics and identified conserved, hierarchically organized regions of the tumor microenvironment, termed “spatial groups.” Link in the comments 👇 #CancerResearch

On July 22, the @FDA approved zidesamtinib (Jideytro) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have already received at least one ROS1 tyrosine kinase inhibitor (TKI). Link in the comments 👇 #LungCancer #NSCLC #ROS1

A new @nature.com study from the Human Cancer Models Initiative (HCMI) presents a large, deeply characterized collection of next-generation patient-derived cancer models. Link in the comments 👇 #CancerResearch #Organoids #CancerModels

The @fda.gov has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with PSMA-positive metastatic androgen pathway modulation-naïve or-sensitive prostate cancer (mAPMN/S). Link in the comments 👇

Antibody-drug conjugates (ADCs) often face a hard limit: when cancer cells downregulate a target like HER2 or exhibit heterogeneous expression, the treatment stops working. A recent @nature.com study introduces a modular in vivo click chemistry approach to bypass this hurdle Link in the comments 👇

The @fda.gov has approved Tudriqev in combination with nivolumab for adults with unresectable or metastatic cutaneous melanoma that progressed following prior anti-PD-1 therapy. Link in the comments 👇

#LabLife Our wonderful interns have completed their internship! 🎓✨ Thank you for your hard work, curiosity, and great energy. We are so proud of you and wish you lots of success in everything ahead! We’ll miss having you in the lab. 💙 #LabLife #Internship #Research #TeamScience

The tumor microenvironment is not just a mixture of cancer, immune, and stromal cells. Their spatial organization can influence tumor progression and treatment response, but mapping it usually requires complex and expensive technologies. Link in the comments 👇

Despite a turbulent year at the FDA, 46 new therapeutic agents received CDER approval in 2025, keeping the annual number well above the historical average of 36 approvals per year since 1993. Link in the comments 👇

#LabLife Happy Birthday to Nikita Kuznetsov! 🎉 You're a true deep thinker who brings a reflective perspective to our team ❤️and we really appreciate how you help everyone analyse their ideas and propose new experiments using your deep chemistry knowledge 💊

A new @science.org study shows that the time of antigen exposure influences how dendritic cells program CD8⁺ T-cell memory through their intrinsic circadian clock, with important implications for vaccination and immunotherapy. Link in the comments 👇

Can a single CAR T-cell infusion lead to decade-long remission in B-cell lymphoma? A new @nejm.org study reports some of the longest follow-up data available for anti-CD19 CAR T-cell therapy. Link in the comments 👇 #Oncology #CARTcell #CellTherapy